FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2944339954> ?p ?o ?g. }

• W2944339954 endingPage "2784.e4" @default.
• W2944339954 startingPage "2776" @default.
• W2944339954 abstract "Background & AimsThere are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD).MethodsWe performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3–12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression.ResultsAt enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37–0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31–0.82). Among individuals with baseline F0–F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43–0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35–0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81–1.05).ConclusionsIn a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time. There are few data from prospective studies on the effects of aspirin on fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). We performed a prospective cohort study of 361 adults with biopsy-confirmed NAFLD, from 2006 through 2015, examined every 3–12 months for incident advanced fibrosis defined using serial measurements of validated indices (the Fibrosis-4, NAFLD fibrosis score, and aspartate aminotransferase to platelet ratio indices). Histologic analyses of liver biopsies collected at baseline were performed by a blinded pathologist. Information collected at baseline and at each examination included frequency and duration of aspirin and nonsteroidal anti-inflammatory drug (NSAID) use. Using multivariable-adjusted logistic regression, we estimated the association of aspirin use with prevalent steatohepatitis (NASH) and fibrosis. Using multivariable-adjusted Cox proportional hazards modeling, we estimated the association between aspirin use and risk for fibrosis progression. At enrollment, 151 subjects used aspirin daily. Compared with non-regular use, daily aspirin use was associated with significantly lower odds of NASH (adjusted odds ratio, 0.68; 95% CI, 0.37–0.89) and fibrosis (adjusted odds ratio, 0.54; 95% CI, 0.31–0.82). Among individuals with baseline F0–F2 fibrosis (n = 317), 86 developed advanced fibrosis over 3692 person-years. Daily aspirin users had significantly lower risk for developing incident advanced fibrosis vs non-regular users (adjusted hazard ratio [aHR], 0.63; 95% CI, 0.43–0.85). This relationship appeared to be duration dependent (adjusted P trend=.026), with the greatest benefit found with at least 4 years or more of aspirin use (aHR, 0.50; 95% CI, 0.35–0.73). Conversely, use of nonaspirin NSAIDs was not associated with risk for advanced fibrosis (aHR, 0.93; 95% CI, 0.81–1.05). In a prospective study of patients with biopsy-proven NAFLD, daily aspirin use was associated with less severe histologic features of NAFLD and NASH, and lower risk for progression to advanced fibrosis with time." @default.
• W2944339954 created "2019-05-16" @default.
• W2944339954 creator A5012423011 @default.
• W2944339954 creator A5024249330 @default.
• W2944339954 creator A5035211037 @default.
• W2944339954 creator A5041452029 @default.
• W2944339954 creator A5068835941 @default.
• W2944339954 creator A5083410949 @default.
• W2944339954 creator A5084857300 @default.
• W2944339954 date "2019-12-01" @default.
• W2944339954 modified "2023-10-16" @default.
• W2944339954 title "Daily Aspirin Use Associated With Reduced Risk For Fibrosis Progression In Patients With Nonalcoholic Fatty Liver Disease" @default.
• W2944339954 cites W1832132481 @default.
• W2944339954 cites W1964572117 @default.
• W2944339954 cites W1997865776 @default.
• W2944339954 cites W2026656096 @default.
• W2944339954 cites W2038981426 @default.
• W2944339954 cites W2063027176 @default.
• W2944339954 cites W2063437798 @default.
• W2944339954 cites W2064387090 @default.
• W2944339954 cites W2066190799 @default.
• W2944339954 cites W2067740038 @default.
• W2944339954 cites W2068860147 @default.
• W2944339954 cites W2081324449 @default.
• W2944339954 cites W2098577478 @default.
• W2944339954 cites W2108941700 @default.
• W2944339954 cites W2110934550 @default.
• W2944339954 cites W2112496618 @default.
• W2944339954 cites W2121815683 @default.
• W2944339954 cites W2121853618 @default.
• W2944339954 cites W2129639561 @default.
• W2944339954 cites W2205934650 @default.
• W2944339954 cites W2229541017 @default.
• W2944339954 cites W2267196191 @default.
• W2944339954 cites W2314572915 @default.
• W2944339954 cites W2331422116 @default.
• W2944339954 cites W2339836793 @default.
• W2944339954 cites W2594904924 @default.
• W2944339954 cites W2607296514 @default.
• W2944339954 cites W2622132351 @default.
• W2944339954 cites W2734724639 @default.
• W2944339954 cites W2756046779 @default.
• W2944339954 cites W2895128760 @default.
• W2944339954 cites W3036643429 @default.
• W2944339954 cites W4212792302 @default.
• W2944339954 cites W90736706 @default.
• W2944339954 doi "https://doi.org/10.1016/j.cgh.2019.04.061" @default.
• W2944339954 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6842070" @default.
• W2944339954 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31077838" @default.
• W2944339954 hasPublicationYear "2019" @default.
• W2944339954 type Work @default.
• W2944339954 sameAs 2944339954 @default.
• W2944339954 citedByCount "96" @default.
• W2944339954 countsByYear W29443399542019 @default.
• W2944339954 countsByYear W29443399542020 @default.
• W2944339954 countsByYear W29443399542021 @default.
• W2944339954 countsByYear W29443399542022 @default.
• W2944339954 countsByYear W29443399542023 @default.
• W2944339954 crossrefType "journal-article" @default.
• W2944339954 hasAuthorship W2944339954A5012423011 @default.
• W2944339954 hasAuthorship W2944339954A5024249330 @default.
• W2944339954 hasAuthorship W2944339954A5035211037 @default.
• W2944339954 hasAuthorship W2944339954A5041452029 @default.
• W2944339954 hasAuthorship W2944339954A5068835941 @default.
• W2944339954 hasAuthorship W2944339954A5083410949 @default.
• W2944339954 hasAuthorship W2944339954A5084857300 @default.
• W2944339954 hasBestOaLocation W29443399541 @default.
• W2944339954 hasConcept C126322002 @default.
• W2944339954 hasConcept C156957248 @default.
• W2944339954 hasConcept C188816634 @default.
• W2944339954 hasConcept C207103383 @default.
• W2944339954 hasConcept C2776954865 @default.
• W2944339954 hasConcept C2777628954 @default.
• W2944339954 hasConcept C2778772119 @default.
• W2944339954 hasConcept C2779134260 @default.
• W2944339954 hasConcept C2780559512 @default.
• W2944339954 hasConcept C44249647 @default.
• W2944339954 hasConcept C50382708 @default.
• W2944339954 hasConcept C71924100 @default.
• W2944339954 hasConcept C90924648 @default.
• W2944339954 hasConceptScore W2944339954C126322002 @default.
• W2944339954 hasConceptScore W2944339954C156957248 @default.
• W2944339954 hasConceptScore W2944339954C188816634 @default.
• W2944339954 hasConceptScore W2944339954C207103383 @default.
• W2944339954 hasConceptScore W2944339954C2776954865 @default.
• W2944339954 hasConceptScore W2944339954C2777628954 @default.
• W2944339954 hasConceptScore W2944339954C2778772119 @default.
• W2944339954 hasConceptScore W2944339954C2779134260 @default.
• W2944339954 hasConceptScore W2944339954C2780559512 @default.
• W2944339954 hasConceptScore W2944339954C44249647 @default.
• W2944339954 hasConceptScore W2944339954C50382708 @default.
• W2944339954 hasConceptScore W2944339954C71924100 @default.
• W2944339954 hasConceptScore W2944339954C90924648 @default.
• W2944339954 hasFunder F4320308400 @default.
• W2944339954 hasFunder F4320332161 @default.
• W2944339954 hasFunder F4320337351 @default.
• W2944339954 hasIssue "13" @default.
• W2944339954 hasLocation W29443399541 @default.

• next